APC/C substrates: how are they disengaged from their non-degraded binding partners?
Sector: Hospital • Location: Netherlands
Source: EU Funding & Tenders Portal
The anaphase promoting complex/ cyclosome (APC/C) is an E3 ubiquitin ligase that controls the cell division cycle by targeting main cell cycle regulators for proteasomal degradation, thereby ensuring error-free cell division and safeguarding genome stability. Its foremost activity is during cell division, or mitosis, when two sets of sister chromatids are equally divided over two newly formed daug
- Status
- Closed
- Sector
- Hospital
- Location
- Netherlands
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about APC/C substrates: how are they disengaged from their non-degraded binding partners?
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The anaphase promoting complex/ cyclosome (APC/C) is an E3 ubiquitin ligase that controls the cell division cycle by targeting main cell cycle regulators for proteasomal degradation, thereby ensuring error-free cell division and safeguarding genome stability. Its foremost activity is during cell division, or mitosis, when two sets of sister chromatids are equally divided over two newly formed daughter cells. Intriguingly, APC/C substrates that are degraded at the metaphase-to-anaphase transition have binding partners, which are not degraded. It remains a mystery how the APC/C controls degradation of the substrates and leaves the binding partners undisturbed. My objective is to clarify the molecular mechanism of substrate-binding partner disengagement, and determine the impact of disengagement on substrate degradation, to ensure controlled sister chromatid separation and genome integrity. First, I propose to identify the precise timing of disengagement during the process of ubiquitination, at the molecular level: this will give fundamental insight into disengagement control (Objective 1). Next, I will study ubiquitination at the proteomics level, by unraveling how Lysine-choice, and ubiquitin chain topology affect disengagement (Objective 2). Finally, I will combine conventional molecular biology methods with advanced microscopy techniques to investigate the importance of controlled substrate-binding partner disengagement for substrate degradation and genome stability (Objective 3). I will employ a multi-disciplinary approach, combining molecular biology, proteomics, and in vivo cell biology approaches to resolve this fundamental biological question. The identified mechanism may provide insights into ternary complex formation of the APC/C and its substrates, which will enable translation to develop targeted-protein-degradation drugs. |
Location
Country | Netherlands |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2026-02-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Netherlands
- Bristol Myers Squibb’s New CAR-T Cell Therapy Facility, Leiden, Netherlands
- Celtic Medical
- The NL Digital Hospital
- Rosalind Franklin Biotechnology Centre, Delft, Netherlands
- HALIX cGMP Biopharmaceutical Facility, Leiden
- Fujifilm’s Cell Culture Media Manufacturing Facility, Netherlands
- SHINE Medical Isotope Production Facility, Veendam, Netherlands
- OSKAR
